Fecal calprotectin: A marker for clinical differentiation of microscopic colitis and irritable bowel syndrome

Clinical and Experimental Gastroenterology

Volumn 9, Issue , 2016, Pages 97-103

  von Arnim, Ulrike ^a   Wex, Thomas ^a   Ganzert, Christine ^a   Schulz, Christian ^a   Malfertheiner, Peter ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Chronic diarrhea; Diarrhea; Fecal calprotectin; IBS; Irritable bowel syndrome; Microscopic colitis

Indexed keywords

BIOLOGICAL MARKER; CALGRANULIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EXAMINATION; COLON BIOPSY; COLONOSCOPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFECATION; DIFFERENTIAL DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES LEVEL; FEMALE; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; IRRITABLE COLON; MALE; MICROSCOPIC COLITIS; PROTEIN ANALYSIS; RAPID TEST; REMISSION; SYMPTOM; VERY ELDERLY;

EID: 84964896166     PISSN: None     EISSN: 11787023     Source Type: Journal    
DOI: 10.2147/CEG.S97701     Document Type: Article

References (32)

1. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006; 130:1480-1491.
2. Kuiken SD, Lindeboom R, Tytgat GN, Boeckxstaens GE. Relationship between symptoms and hypersensitivity to rectal distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2005;22(2):157-164.
3. Ford AC, Spiegel BMR, Talley NJ, Moayyedi P. Small bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2009;7:1279-1286.
4. Kassinen A, Krogius- Kurikka L, Makivoukko H, et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology. 2007;133:24-33.
5. Ford AC, Talley NJ. Mucosal inflammation as a potential etiologic factor in irritable bowel syndrome: a systematic review. J Gastroenterol. 2011;46:421-431.
6. Guagnozzi D, Lucendo AJ, Angueira-Lapeña T, González-Castillo S, Tenias Burillo JM. Prevalence and incidence of microscopic colitis in patients with diarrhoea of unknown aetiology in a region in central Spain. Dig Liver Dis. 2012;44:384-388.
7. Bohr J, Tysk C, Eriksson S, Järnerot G. Collagenous colitis in Orebro, Sweden, an epidemiological study. 1984-1993. Gut. 1995;37:394-397.
8. Olesen M, Eriksson S, Bohr J, Järnerot G, Tysk C. Microscopic colitis: a common diarrhoeal disease. An epidemiological study in Orebro, Sweden, 1993-1998. Gut. 2004;53:346-350.
9. Fernández-Bañares F, Salas A, Forné M, Esteve M, Espinós J, Viver JM. Incidence of collagenous and lymphocytic colitis: a 5-year population-based study. Am J Gastroenterol. 1999;94:418.
10. Pardi DS, Loftus EV Jr, Smyrk TC, et al. The epidemiology of microscopic colitis: a population based study in Olmsted County, Minnesota. Gut. 2007;56:504-508.
11. Limsui D, Pardi DS, Camilleri M, et al. Symptomatic overlap between irritable bowel syndrome and microscopic colitis. Inflamm Bowel Dis. 2007;13:175-181.
12. Fagerhol MK, Andersson KB, Naess-Andresen CF, Brandtzaeg P, Dale I. Calprotectin (the L1 leukocyte protein). In: Smith VL, Dedman JR, editors. Stimulus Response Coupling: The Role of Intracellular Calcium-Binding Proteins. Boca Raton, FL: CRC; 1990:187-210.
13. Johne B, Fagerhol MK, Lyberg T, et al. Functional and clinical aspects of the myelomonocyte protein calprotectin. Mol Pathol. 1997;50:113-123.
14. Tibble J, Sigthorsson G, Foster R, Sherwood R, Fagerhol M, Bjarnason I. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut. 2001;49:402-408.
15. Tibble J, Teahon K, Thjodleifsson B, et al. A simple method for assessing intestinal inflammation in Crohn’s disease. Gut. 2000;47:506-513.
16. Carroccio A, Iacono G, Cottone M, et al. Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem. 2003;49:861-867.
17. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000;119:15-22.
18. Lettesjö H, Hansson T, Peterson C, et al. Detection of inflammatory markers in stools from patients with irritable bowel syndrome and collagenous colitis. Scand J Gastroenterol. 2006;41:54-59.
19. Wildt S, Nordgaard-Lassen I, Bendtsen F, Rumessen JJ. Metabolic and inflammatory faecal markers in collagenous colitis. Eur J Gastroenterol Hepatol. 2007;19:567-574.
20. Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology. 2002;123:450-460.
21. Limburg PJ, Ahlquist DA, Sandborn WJ, et al. Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. Am J Gastroenterol. 2000;95:2831-2837.
22. Lazenby AJ, Yardley JH, Giardiello FM, Jessurun, J, Bayless TM. Lymphocytic (“microscopic”) colitis: a comparative histopathologicic study with particular reference to collagenous colitis. Hum Pathol. 1989;20:18-28.
23. Baert F, Wouters K, D’Haens G, et al. Lymphocytic colitis: a distinct clinical entitiy? A clinicopathological confrontation of lymphocytic and collagenous colitis. Gut. 1999;45:375-381.
24. Offnr FA, Jao RV, Lewin KJ, Havelec L, Weinstein WM. Collagenous colitis: a study of the distribution of morphological abnormalities and their histological detection. Hum Pathol. 1999;33:451-457.
25. Riegler G, Esposito I. Bristol scale stool form. A still valid step in medical practice and clinical research. Tech Coloproctol. 2001;5:163-164.
26. Veestergaard TA, Nielsen SL, Dahlerup JF, Hornung N. Fecal calprotectin. Assessment of a rapid test. Scand J Clin Lab Invest. 2008;68:343-347.
27. D’Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2218-2224.
28. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol. 2008;103:162-169.
29. Wagner M, Peterson CGB, Stolt I, et al. Fecal eosinophil cationic protein as a marker of active disease and treatment outcome in collagenous colitis: a pilot study. Scand J Gastroenterol. 2011;46:849-854.
30. Wagner M, Lampinen M, Sangfelt P, Agnarsdottir M, Carlson M. Budesonide treatment of patients with collagenous colitis restores normal eosinophil and T-cell activity in the colon. Inflamm Bowel Dis. 2010;16:44-48.
31. Ayate G, Ithamukkala S, Sapp H, et al. Prevalence and significance of inflammatory bowel disease- like morphological features in collagenous and lymphocytic colitis. Am J Surg Pathol. 2002;26:1414-1423.
32. Bjørnbak C, Engel PJH, Nielsen PL, Munck LK. Microscopic colitis: clinical findings, topography and persistence of histopathological subgroups. Aliment Pharmacol Ther. 2011;34:1225-1234.